| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | HSN1; LBC1; LCB1; SPT1; SPTI; HSAN1 |
| WB Predicted band size | 53 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human SPTLC1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于SPTLC1抗体的3篇参考文献的简要总结：
1. **文献名称**：*Mutations in SPTLC1 cause hereditary sensory neuropathy type 1*
**作者**：Dawkins JL, et al.
**摘要**：该研究首次发现SPTLC1基因突变与遗传性感觉神经病变1型(HSN1)相关，通过抗体检测发现突变导致神经细胞中鞘脂代谢异常，引发轴突退化。
2. **文献名称**：*SPTLC1 expression and its role in cancer cell apoptosis*
**作者**：Hannun YA, et al.
**摘要**：利用SPTLC1抗体分析其在多种癌细胞中的表达，发现SPTLC1下调会抑制鞘脂合成，诱导癌细胞凋亡，提示其作为潜在治疗靶点。
3. **文献名称**：*Immunohistochemical localization of SPTLC1 in peripheral nerves and tumors*
**作者**：Penno A, et al.
**摘要**：通过SPTLC1抗体进行组织染色，证实其在周围神经中的高表达，并在神经鞘瘤中异常积累，提示其与肿瘤微环境相关。
4. **文献名称**：*SPTLC1 antibody validation for Western blot and flow cytometry*
**作者**：Grosch S, et al.
**摘要**：研究验证了SPTLC1抗体在Western blot和流式细胞术中的特异性，为后续功能研究提供了可靠工具。
以上文献覆盖了SPTLC1在疾病机制、癌症研究和实验技术中的应用。如需具体文章细节，可进一步提供DOI或PMID。
The SPTLC1 (serine palmitoyltransferase long-chain base subunit 1) antibody is a research tool designed to detect and study the SPTLC1 protein, a critical component of the serine palmitoyltransferase (SPT) enzyme complex. SPT catalyzes the first and rate-limiting step in the de novo biosynthesis of sphingolipids, a class of lipids essential for membrane structure, cell signaling, and apoptosis. SPTLC1. together with SPTLC2 or SPTLC3. forms the catalytic core of SPT, which condenses serine and palmitoyl-CoA to generate 3-ketodihydrosphingosine. Dysregulation of SPTLC1 has been implicated in hereditary sensory and autonomic neuropathy type 1 (HSAN1), a rare neurological disorder characterized by sensory loss and ulcerative complications, as well as in cancer and metabolic diseases.
SPTLC1 antibodies are widely used in basic and clinical research to investigate sphingolipid metabolism pathways, disease mechanisms, and therapeutic targets. They enable the detection of SPTLC1 expression levels via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Recent studies also explore SPTLC1's role in modulating cellular responses to stress, inflammation, and chemotherapeutic agents. As sphingolipid imbalances are linked to neurodegeneration, diabetes, and oncogenesis, SPTLC1 antibodies serve as vital tools for understanding disease pathology and developing targeted interventions. Their specificity and reliability are continually optimized to support advances in precision medicine and biomarker discovery.
×
